Jubilant Life gets ANDA final nod for Clomipramine Hydrochloride Capsules to treat OCD

New Delhi: Jubilant Life Sciences Ltd recently announced that Jubilant Pharma Limited, a material wholly-owned subsidiary of the Company, through one of its wholly-owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Clomipramine Hydrochloride Capsules USP 25mg, 50mg and 75mg to treat Obsessive-Compulsive Disorder (OCD).

Clomipramine Hydrochloride Capsules USP 25mg, 50mg and 75mg, are the generic version of Anafranil of SpecGx LLC. The product is indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD), Jubilant said in a filing.

Also Read: Jubilant Life gets USFDA nod for Niacin extended-release tablets

As on June 30, 2019, Jubilant had a total of 96 ANDAs for Oral Solids filed in the US, of which 61 had been approved and 15 Injectable filings, of which 13 had been approved.